EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High‐Risk Screening for Late‐Onset Pompe Disease in Northern China: Prevalence, Genotypic Spectrum, and Diagnostic Challenges

Hang Su, Duoling Li iD, Meng Yu iD, Junhong Guo iD, Xuefan Yu iD, Xiaojing Wei, Xueqin Song, Zhe Zhao iD, Mingming Ma iD, Kai Ma iD, Ting Chang iD, Xiangqi Cao iD und 20 weitere

JIMD Reports · 2026-11 · 67 (6)

DOI: 10.1002/jmd2.70138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JIMD Reports, online erschienen am 13.11.2026. Verfasst von Hang Su und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Shandong Key Laboratory of Mitochondrial Medicine and Rare Diseases, Research Institute of Neuromuscular and Neurodegenerati…. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Late‐onset Pompe disease (LOPD), also known as late‐onset glycogen storage disease Type II, is caused by a genetic deficiency of the lysosomal enzyme acid α‐glucosidase (GAA). LOPD typically results in progressive weakness of the limb‐girdle and respiratory muscles and is often accompanied by the involvement of other systems, such as skeleton, smooth muscle, and the cerebrovascular system. The incidence of LOPD in China remains unknown, underscoring the need for large‐scale epidemiological studies to better characterize the clinical spectrum. This prospective, multicenter, observational cohort study was conducted across 39 neurology centers in 12 northern Chinese provinces. A novel pragmatic approach was utilized, which included the development and application of a standardized high‐risk profile for LOPD suspicion, derived from collective diagnostic and therapeutic experience throughout the region. Individuals meeting 2 or more criteria in this predefined high‐risk profile were enrolled. Subsequent screening involved initial analysis of GAA enzyme activity using dried blood spot (DBS) testing and patients with deficient enzyme activity underwent confirmatory genetic testing to establish a definitive LOPD diagnosis. Between January 2022 and December 2024, 1878 high‐risk patients were enrolled. Screening identified 46 patients (2.45%) diagnosed with LOPD based on DBS analysis and subsequent genetic confirmation. This study demonstrates a significant prevalence of LOPD among a clinically high‐risk population in Northern China. These findings underscore the critical importance of targeted screening programs for early identification. Early diagnosis enables timely initiation of enzyme replacement therapy (ERT), which can significantly mitigate the disease course, improve quality of life, and reduce long‐term healthcare burden.

Schlagwörter

Stichwörter der Autor:innen

GAANorthern Chinadried blood spothigh‐risk screeninglate‐onset Pompe disease

Autor:innen und Institutionen

  • Department of Neurology, Shandong Key Laboratory of Mitochondrial Medicine and Rare Diseases, Research Institute of Neuromuscular and Neurodegenerative Diseases Qilu Hospital of Shandong University Jinan China.
  • Department of Neurology Peking University First Hospital Beijing China.
  • Department of Neurology The First Hospital of Shanxi Medical University Taiyuan China.
  • Department of Neurology and Neuroscience Center The First Affiliated Hospital of Jilin University Changchun Jilin China.
  • Department of Neurology The Second Hospital of Hebei Medical University and Neurological Laboratory of Hebei Province Shijiazhuang Hebei China.
  • Department of Neurology Hebei Medical University Third Hospital Shijiazhuang Hebei China.

ORCID-Profile: Duoling Li, Meng Yu, Junhong Guo, Xuefan Yu, Zhe Zhao, Mingming Ma, Kai Ma, Ting Chang, Xiangqi Cao, Zaiqiang Zhang, Weili Zhao, Ying Li, Chuanzhu Yan, Zhaoxia Wang, Yuying Zhao

Förderung

  • Sanofi

Zitieren

APA

Su, H., Li, D., Yu, M., Guo, J., Yu, X., Wei, X., Song, X., Zhao, Z., Ma, M., Ma, K., Chang, T., Cao, X., Li, X., Kang, J., Zhang, Z., Han, H., Wang, Z., Di, L., Xiong, T., …, & Zhao, Y. (2026). High‐Risk Screening for Late‐Onset Pompe Disease in Northern China: Prevalence, Genotypic Spectrum, and Diagnostic Challenges. JIMD Reports, 67(6). https://doi.org/10.1002/jmd2.70138

Vancouver

Su H, Li D, Yu M, Guo J, Yu X, Wei X, et al. High‐Risk Screening for Late‐Onset Pompe Disease in Northern China: Prevalence, Genotypic Spectrum, and Diagnostic Challenges. JIMD Reports. 2026;67(6). doi:10.1002/jmd2.70138

BibTeX
@article{Su2026,
  author = {Su, Hang and Li, Duoling and Yu, Meng and Guo, Junhong and Yu, Xuefan and Wei, Xiaojing and Song, Xueqin and Zhao, Zhe and Ma, Mingming and Ma, Kai and Chang, Ting and Cao, Xiangqi and Li, Xia and Kang, Juan and Zhang, Zaiqiang and Han, Hong and Wang, Zhuyan and Di, Li and Xiong, Ting and Sun, Sha and Wu, Jun and Zhang, Shu and Zhao, Cuiping and Sun, Yuan and Zhao, Weili and Wang, Zhiyun and Zhang, Yali and Wang, Haiping and Li, Ying and Yan, Chuanzhu and Wang, Zhaoxia and Zhao, Yuying},
  title = {High‐Risk Screening for Late‐Onset Pompe Disease in Northern China: Prevalence, Genotypic Spectrum, and Diagnostic Challenges},
  journal = {JIMD Reports},
  year = {2026},
  volume = {67},
  number = {6},
  doi = {10.1002/jmd2.70138}
}
Kostenlos starten →